FULCRUM THERAPEUTICS, INC. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
FULCRUM THERAPEUTICS, INC. (FULC) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 11.65 million shares for the 3-month period ending 2026-06-30, per its S-4 filed 2026-09-02.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-09-02
- FULCRUM THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-06-30 was 11.65M shares, a 4.13% decline year-over-year.
- FULCRUM THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 14.02M shares, a 15.89% increase year-over-year.
- FULCRUM THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-09-30 was 11.94B shares, a 10.37% increase year-over-year.
- FULCRUM THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-06-30 was 12.15M shares, a 99.85% decline year-over-year.
- FULCRUM THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 10.05M shares, a 52.68% increase from fiscal 2022.
- FULCRUM THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 6.58M shares, a 26.59% increase from fiscal 2021.
- FULCRUM THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2021 was 5.20M shares, a 68.34% increase from fiscal 2020.
- FULCRUM THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2020 was 3.09M shares, a 14.17% increase from fiscal 2019.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | 11.65M shares S-4 · filed 2026-09-02 | 11.65M shares S-4 · filed 2026-09-02 | |||||
| 2026-03-31 | 14.02M shares 10-Q · filed 2026-04-27 | ||||||
| 2025-12-31 | 11.72M shares S-4 · filed 2026-09-02 | ||||||
| 2025-09-30 | 11.94B shares 10-Q · filed 2025-10-29 | 11.94B shares 10-Q · filed 2025-10-29 | |||||
| 2025-06-30 | 12.15M shares S-4 · filed 2026-09-02 | 12.15B shares 10-Q · filed 2025-07-29 | 12.15M shares S-4 · filed 2026-09-02 | 12.15B shares 10-Q · filed 2025-07-29 | |||
| 2025-03-31 | 12.10M shares 10-Q · filed 2026-04-27 | 12.10B shares 10-Q · filed 2025-05-01 | |||||
| 2024-12-31 | 9.40M shares S-4 · filed 2026-09-02 | ||||||
| 2024-09-30 | 10.82B shares 10-Q · filed 2025-10-29 | 10.82K shares 10-Q · filed 2024-11-13 | 7.50B shares 10-Q · filed 2025-10-29 | 7.50K shares 10-Q · filed 2024-11-13 | |||
| 2024-06-30 | 8.06B shares 10-Q · filed 2025-07-29 | 8.05K shares 10-Q · filed 2024-07-31 | 7.32B shares 10-Q · filed 2025-07-29 | 7.32K shares 10-Q · filed 2024-07-31 | |||
| 2024-03-31 | 12.42B shares 10-Q · filed 2025-05-01 | 12.42M shares 10-Q · filed 2024-05-13 | |||||
| 2023-12-31 | 10.05M shares 10-K · filed 2025-02-25 | ||||||
| 2023-09-30 | 10.19K shares 10-Q · filed 2024-11-13 | 10.19M shares 10-Q · filed 2023-11-07 | 10.19K shares 10-Q · filed 2024-11-13 | 10.19M shares 10-Q · filed 2023-11-07 | |||
| 2023-06-30 | 10.20K shares 10-Q · filed 2024-07-31 | 10.20M shares 10-Q · filed 2023-08-03 | 10.20K shares 10-Q · filed 2024-07-31 | 10.20M shares 10-Q · filed 2023-08-03 | |||
| 2023-03-31 | 6.98M shares 10-Q · filed 2024-05-13 | ||||||
| 2022-12-31 | 6.58M shares 10-K · filed 2024-02-27 | ||||||
| 2022-09-30 | 6.02M shares 10-Q · filed 2023-11-07 | 6.02M shares 10-Q · filed 2023-11-07 | |||||
| 2022-06-30 | 6.25M shares 10-Q · filed 2023-08-03 | 6.25M shares 10-Q · filed 2023-08-03 | |||||
| 2022-03-31 | 6.57M shares 10-Q · filed 2023-05-15 | ||||||
| 2021-12-31 | 5.20M shares 10-K/A · filed 2023-06-26 | ||||||
| 2021-09-30 | 4.98M shares 10-Q · filed 2022-11-08 | 4.98M shares 10-Q · filed 2022-11-08 | |||||
| 2021-06-30 | 4.72M shares 10-Q · filed 2022-08-11 | 4.72M shares 10-Q · filed 2021-08-10 | 4.72M shares 10-Q · filed 2022-08-11 | 4.72M shares 10-Q · filed 2021-08-10 | |||
| 2021-03-31 | 4.29M shares 10-Q · filed 2022-05-09 | ||||||
| 2020-12-31 | 3.09M shares 10-K/A · filed 2023-06-26 | ||||||
| 2020-09-30 | 3.05M shares 10-Q · filed 2021-11-04 | 3.05M shares 10-Q · filed 2021-11-04 | |||||
| 2020-06-30 | 3.04M shares 10-Q · filed 2021-08-10 | 3.04M shares 10-Q · filed 2021-08-10 | |||||
| 2020-03-31 | 3.40M shares 10-Q · filed 2021-05-06 | ||||||
| 2019-12-31 | 2.70M shares 10-K/A · filed 2023-06-23 | ||||||
| 2019-09-30 | 2.76M shares 10-Q · filed 2020-11-10 | 2.76M shares 10-Q · filed 2020-11-10 | |||||
| 2019-06-30 | 18.56M shares 10-Q · filed 2020-08-11 | 18.56M shares 10-Q · filed 2020-08-11 | |||||
| 2019-03-31 | 18.63M shares 10-Q · filed 2020-05-13 | ||||||
| 2018-12-31 | 16.00M shares 10-K · filed 2020-03-05 | ||||||
| 2018-09-30 | 15.85M shares 10-Q · filed 2019-11-14 | 15.85M shares 10-Q · filed 2019-11-14 | |||||
| 2018-06-30 | 10.16M shares 10-Q · filed 2019-08-26 | 10.16M shares 10-Q · filed 2019-08-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |